Canopy Growth (TSX:WEED)(NYSE:CGC) has been on the rise again. Last week, the stock closed at over $67 — the last time it did that was back in late January. The last time the share price closed at over $70 was back in October, right around legalization and before pot stocks took a big hit.

In case you haven't noticed, big things are happening with the legal marijuana industry. It's already growing at an impressive pace, and excitement surrounding the legal pot industry really took off following the legalization of recreational marijuana in Canada in October. Eventually, Wall Street is looking for the cannabis industry to generate $50 billion to $75 billion in sales by the end of the next decade.

U.S. medical cannabis producer Columbia Care begins trading on Canada’s NEO Exchange

As the cannabis industry finally takes off after nearly a century of prohibition, investors have neglected to ask themselves a central question. It might seem too obvious to even ask, but as you’ll see in this report, that is not the case at all. That question is, who should cannabis be marketed to?

I’m going to make the case here that the big and familiar players in the cannabis industry are all ignoring this critical question. I’m going to show you how one small and extremely undervalued ultra-premium focused cannabis firm is one of the very few answering it correctly.

Zenabis Global Inc. (TSXV: ZENA)("Zenabis" or the "Company") is pleased to announce that it has entered into a binding term sheet for a three-year supply arrangement with leading German pharmaceutical research company Farmako GmbH ("Farmako") for: (1) the supply of biosynthetically produced pure CBD isolate oil (99.9%) from Farmako to Zenabis for sale in Canada; and (2) the supply of European Union Good Manufacturing Practices ("EU GMP") certified cannabis cultivated in Zenabis' indoor facilities in Canada for sale by Farmako to the German medical market.

The upstart NEO Exchange scored its first billion-dollar corporate listing today with U.S. medical cannabis producer Columbia Care.

The New-York based cultivator, manufacturer and dispensary operator made its debut with a market capitalization of more than $2-billion.

The stock exchange said Monday the multi-state operator, with a presence in roughly 15 states, is the first company to list on the NEO with an enterprise value of over $1 billion.

"This is an exciting time to be partnering with a leader in the U.S. cannabis sector as it moves into its next phase and looks to raise capital on the North American public markets," NEO chief executive Jos Schmitt said in a statement.

Columbia Care trades under the symbol CCHW.

Cannabis stocks had a lackluster start to the week, with many stocks flat on Monday.  

The North American Marijuana Index, which tracks the top cannabis stocks in the US and Canada, nudged up 0.2% to 303.02 by Monday's close. The Horizons Marijuana Life Sciences Index ETF fared better, up 1.7% at C$21.59.

Buds

There were a number of buds in the mix on Monday.

Choom™ (CSE: CHOO; OTCQB: CHOOF) is pleased to announce that on Friday, April 26, 2019 , the Alcohol and Gaming Commission of Ontario (“AGCO”) issued a Retail Operator Licence to Lisa Bigioni , and issued a Retail Store Authorization for her Choom-branded cannabis store in Niagara Falls, Ontario , which is expected to open in May 2019 .

In accordance with the AGCO’s requirements, Ms. Bigioni, as a licensed operator, may finalize her store set-up, including ordering and receiving cannabis product and cannabis accessories into her store ahead of opening for business.

 The AGCO will also conduct a pre-opening inspection to ensure the store is ready to open for business and sell cannabis products to the public in accordance with all applicable regulations.

For opportunistic investors looking to make money, there's arguably no industry generating more buzz than legal marijuana. Only about once or twice a generation do we really see an industry grow as quickly as legal cannabis may be able to over the next decade. If all goes well, Wall Street foresees between $50 billion and $75 billion in annual worldwide sales by 2029 to 2030.

Since growth like this doesn't come around all the time, marijuana growers have been busy expanding their capacity by any means necessary.

There’s so much to like about the small but major procurement, licensing and strategic partnership deal that Aurora Cannabis (TSX:ACB)(NYSE:ACB) announced with a growing patented technology player EnWave Corp (TSXV:ENW) on Friday, April 26.

The latest deal could significantly improve operating efficiency, reduce working capital requirements, and allow bulk drying of cannabis materials at a fraction of the time while offering the marijuana firm a partnership and a chance to share in royalty payments from other licensees within large territories, yet on a small investment of just $10 million.